Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbations

Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbation

On Monday, AstraZeneca PLC announced that Phase IIa study of benralizumab, an experimental drug for the treatment of Chronic Obstructive Pulmonary Disease (COPD), was published in 'The Lancet Respiratory Medicine' medical journal.

This drug is specially designed for the patients who do not respond effectively to the traditionally available inhalers. COPD is a disease related to smoking.

As per the study, the drug did not meet its primary endpoint, as benralizumab was not able to reduce the rate of serious attacks called acute exacerbations, when compared with a placebo. But it showed significant improvements in the lung function in the overall population.

Sources revealed that the study's data will be presented at the 2014 European Respiratory Society International Congress in Munich, Germany, along with other data from the company's respiratory profile. However, GlaxoSmithKline and Teva Pharmaceutical Industries are also working to prepare a rival product of the drug.

Shares of AstraZeneca on Monday morning were reported to be down by 0.8% at 4,517.50 pence.

Despite the mix results of the mid-stage, AstraZeneca in July made an announcement of starting a final-stage Phase III program for benralizumab in COPD, despite the mix results of the mid stage.

Experts said that benralizumab is so-called anti-interleukin-5 antibody that helps to reduce white blood cells causing lung disorders. Initially, main focus of the drug was severe asthma, but COPD is another major market opportunity for AstraZeneca and the company believes that it will be able to dominate in the area.

Bing Yao, head of respiratory drug development at AstraZeneca's MedImmune unit, said, "COPD is a highly heterogeneous disease and we are working to better understand patient subtypes, identify potential biomarkers and tailor therapies to achieve the best outcomes for patients."


User login



You May Have Missed...

eBay to separate from PayPal in three weeks
Sat, 06/27/2015 - 13:59

On Friday, eBay's board of directors gave its final stamp of approval to separate from payment processing company PayPal.

John Donahoe,...


Nigeria Update

Fresh Polio Cases lead to WHO Travel Restrictions on Pakistan and Syria
Tue, 05/06/2014 - 00:45

World Health Organization has slapped international travel restrictions on Pakistan, Cameroon...


Economy Watch

Yellen Indicates Interest Rate Increase if the Economy Continues to Perform
Sat, 05/23/2015 - 08:58

This month, the selloff in Treasuries had a connection to the bond commotion in Europe. Janet...


Health Tonight

Scientists Debunk belief that Global Warming reduces Winter-related Deaths
Wed, 06/24/2015 - 12:10

A new study from the researchers from the Columbia University‘s Mailman School of Public Health...


Science Tonight

NASA Working On Transforming Mars to Make It Habitable For Humans
Fri, 06/26/2015 - 12:46

An ongoing program at the Pentagon’s advanced research division is looking forward to create...


UK News

University student creates cookery kit to cook insects
Fri, 05/15/2015 - 01:51

AnEdinburgh student has developed a cookery kit in order to encourage people to eat insects,...


Pharmaceuticals

Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbation
Mon, 09/08/2014 - 13:17

On Monday, AstraZeneca PLC announced that Phase IIa study of benralizumab, an experimental drug...


US News

New iPhone App to Carry out Ever Largest Nationwide Health Study of LGBT
Fri, 06/26/2015 - 13:04

A team of researchers is to carry out the largest ever nationwide health study of LGBT...


Technology Tonight

Apple trying to ensure greater performance standards from its older devices
Sat, 05/23/2015 - 08:31

In what apparently is somewhat of a 'back to basics' move by US tech giant Apple, the company...